Ovarian cancer (OC), accounting for approximately 200,000 deaths worldwide annually, is a heterogeneous disease showing major differences in terms of its incidence, tumor behavior, and outcomes across histological subtypes. In OC, primary chemotherapy, paclitaxel carboplatin, bevacizumab, and PARP inhibitors have shown prolonged progression-free survival and a favorable overall response rate compared to conventional treatments. However, treatment options for platinum-resistant recurrence cases are limited, with no effective therapies that significantly prolong the prognosis. Recently, mirvetuximab soravtansine, an alpha-folate receptor (FRα)-targeted antibody-drug conjugate (ADC), was approved by the US Food and Drug Administration for patients with FRα-positive recurrent epithelial OC (EOC). This approval was based on a Phase II study, which demonstrated its efficacy in such patients. ADCs comprise an antibody, a linker, and a payload, representing new concept agents without precedence. Advanced clinical studies are developing ADCs for patients with OC, targeting solid tumors such as gynecologic cancer. Ongoing clinical trials are evaluating ADCs targeting FRα and human epidermal growth factor receptor 2, trophoblast cell surface antigen-2, sodium-dependent phosphate transport protein 2B, and cadherin-6 in Phase II/III studies. In this review, we summarize the existing evidence supporting the use of ADCs in OC, discuss ongoing clinical trials and preclinical studies, and explore the potential of these innovative agents to address the challenges in OC treatment.
卵巢癌（OC）是一种异质性疾病，全球每年约导致20万人死亡，其不同组织学亚型在发病率、肿瘤行为和预后方面存在显著差异。在卵巢癌治疗中，以紫杉醇卡铂、贝伐珠单抗和PARP抑制剂为主的初始化疗方案相较于传统治疗，已显示出更长的无进展生存期和良好的总体缓解率。然而，针对铂类耐药复发患者的治疗选择有限，目前尚无能显著延长预后的有效疗法。近期，靶向叶酸受体α（FRα）的抗体偶联药物（ADC）米伐妥昔单抗索拉坦辛已获美国食品药品监督管理局批准，用于FRα阳性复发性上皮性卵巢癌（EOC）患者。该批准基于一项II期研究，证实了该药物对此类患者的疗效。ADC由抗体、连接子和有效载荷三部分组成，代表了一种前所未有的新型药物概念。针对卵巢癌等实体瘤（如妇科肿瘤）的ADC药物正在通过高级别临床研究进行开发。目前正在进行的II/III期临床试验正在评估靶向FRα、人表皮生长因子受体2、滋养层细胞表面抗原2、钠依赖性磷酸盐转运蛋白2B以及钙黏蛋白6的ADC药物。本综述总结了支持ADC在卵巢癌中应用的现有证据，探讨了正在进行的临床试验和临床前研究，并展望了这类创新药物应对卵巢癌治疗挑战的潜力。
Antibody-Drug Conjugates: The New Treatment Approaches for Ovarian Cancer
肿瘤(癌症)患者之家